A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
GABAergic cells
NKCC1 inhibitor
Parkinson's disease
bumetanide
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
revised:
05
10
2023
received:
17
08
2023
accepted:
09
01
2024
medline:
31
1
2024
pubmed:
31
1
2024
entrez:
31
1
2024
Statut:
aheadofprint
Résumé
Acting on the main target of dopaminergic cells, the striatal γ-aminobutyric acid (GABA)-ergic cells, might be a new way to treat persons with Parkinson's disease (PD). The objective of this study was to assess the efficacy of bumetanide, an Na-K-Cl cotransporter (NKCC1) inhibitor, to improve motor symptoms in PD. This was a 4-month double-blind, randomized, parallel-group, placebo-controlled trial of 1.75 to 3 mg/day bumetanide as an adjunct to levodopa in 44 participants with PD and motor fluctuations. Compared to the baseline, the mean change in OFF Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score after 4 months of treatment (primary endpoint) did not improve significantly compared with placebo. No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated. There was no evidence in this study that bumetanide has efficacy in improving motor symptoms of PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
BACKGROUND
Acting on the main target of dopaminergic cells, the striatal γ-aminobutyric acid (GABA)-ergic cells, might be a new way to treat persons with Parkinson's disease (PD).
OBJECTIVE
OBJECTIVE
The objective of this study was to assess the efficacy of bumetanide, an Na-K-Cl cotransporter (NKCC1) inhibitor, to improve motor symptoms in PD.
METHODS
METHODS
This was a 4-month double-blind, randomized, parallel-group, placebo-controlled trial of 1.75 to 3 mg/day bumetanide as an adjunct to levodopa in 44 participants with PD and motor fluctuations.
RESULTS
RESULTS
Compared to the baseline, the mean change in OFF Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score after 4 months of treatment (primary endpoint) did not improve significantly compared with placebo. No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated.
CONCLUSIONS
CONCLUSIONS
There was no evidence in this study that bumetanide has efficacy in improving motor symptoms of PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : BA Therapeutics
Informations de copyright
© 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Dorsey ER, Bloem BR. The Parkinson pandemic-a call to action. JAMA Neurol 2018;75(1):9-10. https://doi.org/10.1001/jamaneurol.2017.3299
Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386(9996):896-912. https://doi.org/10.1016/S0140-6736(14)61393-3
Lozovaya N, Eftekhari S, Cloarec R, et al. GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease. Nat Commun 2018;9(1):1422. https://doi.org/10.1038/s41467-018-03802-y
Pieraut S, Laurent-Matha V, Sar C, et al. NKCC1 phosphorylation stimulates neurite growth of injured adult sensory neurons. J Neurosci 2007;27(25):6751-6759. https://doi.org/10.1523/JNEUROSCI.1337-07.2007
Nardou R, Ben-Ari Y, Khalilov I. Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus. J Neurophysiol 2009;101(6):2878-2888. https://doi.org/10.1152/jn.90761.2008
Damier P, Hammond C, Ben-Ari Y. Bumetanide to treat Parkinson disease: a report of 4 cases. Clin Neuropharmacol 2016;39(1):57-59. https://doi.org/10.1097/WNF.0000000000000114
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30(12):1591-1601. https://doi.org/10.1002/mds.26424
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS revision TaskForce. Movement Disorder Society-sponsored revision of the unified Parkinson's disease RatingScale (MDS-UPDRS): scale presentation andclinimetric testing results. Mov Disord 2008;23(15):2129-2170. https://doi.org/10.1002/mds.22340
Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD. Construction of freezing of gait questionnaire for patients with parkinsonism. Parkinsonism Relat Disord 2000;6(3):165-170. https://doi.org/10.1016/s1353-8020(99)00062-0
Goetz CG, Nutt JG, Stebbins GT. The unified dyskinesia rating scale: presentation and clinimetric profile. Mov Disord 2008;23(16):2398-2403. https://doi.org/10.1002/mds.22341
Lemonnier E, Villeneuve N, Sonie S, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl. Psychiatry 2017;7(3):e1056. https://doi.org/10.1038/tp.2017.10
van Andel DM, Sprengers JJ, Oranje B, Scheepers FE, Jansen FE, Bruining H. Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. Mol Autism 2020;11(1):1-14. https://doi.org/10.1186/s13229-020-00335-4
Juarez-Martinez EL, Sprengers JJ, Cristian G, et al. Prediction of behavioral improvement through resting-state EEG and clinical severity in a randomized controlled trial testing bumetanide in autism Spectrum disorder. Biol Psychiatry Cogn Neurosci Neuroimaging 2021;8(3):251-261. https://doi.org/10.1016/j.bpsc.2021.08.009